1. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040 Women’s Health Initiative Trials of Menopausal Hormone Therapy Through Extended Follow-upThere were 342 306 women who were ineligible or unwilling to participate in the hormone therapy trials. The postintervention phase began on the day after participants were instructed to stop study medication use and continued through the original trial completion date. During the extension phase, there was follow-up for those who provided additional consent (conjugated equine estrogens plus medroxyprogesterone acetate or placebo trial: 83% of those eligible and 2.8% dropped out; conjugated equine estrogens alone or placebo trial: 78% of those eligible and 3.0% dropped out). Figure Legend:

2. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040 Health Outcomes in the Overall Study Population in the Women’s Health Initiative Hormone Therapy Trials During the Intervention PhaseCABG indicates coronary artery bypass graft; CEE, conjugated equine estrogens; HR, hazard ratio; MI, myocardial infarction; MPA, medroxyprogesterone acetate; NA, not applicable due to hysterectomy; NR, not reported due to small numbers; PCI, percutaneous coronary intervention; PY, person-years. a Percentages are annualized. b Difference in estimated absolute excess risks (hormone therapy minus placebo). c Indicates CEE alone or CEE plus MPA. d Excludes non–melanoma skin cancer. e In women aged 65 years or older. f In women not reporting condition at baseline. g Collected at year 1. h In symptomatic women aged 50 to 54 years. Figure Legend:

3. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040 Absolute Risks of Health Outcomes by 10-Year Age Groups in the Women’s Health Initiative Hormone Therapy Trials During the Intervention PhaseNone of the age interactions were statistically significant (at the P <.05 level), except for colorectal cancer, all- cause mortality, myocardial infarction, and the global index in the CEE alone trial (details appear in Figure 5). CEE indicates conjugated equine estrogens; MPA, medroxyprogesterone acetate. Figure Legend:

4. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040 Postintervention Health Outcomes and Overall Combined Outcomes (Cumulative Follow-up) in the Overall Study Population in the Women’s Health Initiative Hormone Therapy TrialsThe all cardiovascular events outcome is defined in the Results section. CABG indicates coronary artery bypass graft; CEE, conjugated equine estrogens; HR, hazard ratio; MI, myocardial infarction; MPA, medroxyprogesterone acetate; NA, not applicable because women have had hysterectomy; NR, not reported due to small numbers; PCI, percutaneous coronary intervention; PY, person-years. a The percentages are annualized. b Difference in estimated absolute excess risks (CEE plus MPA or CEE alone minus placebo). c Indicates CEE alone or CEE plus MPA. d Excludes non–melanoma skin cancer. e Includes participants who did not report a prevalent condition at baseline. Figure Legend:

5. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040 Health Outcomes in the Women’s Health Initiative Hormone Therapy Trials During the Intervention Phase According to 10-Year Age Groups at RandomizationCABG indicates coronary artery bypass graft; CEE, conjugated equine estrogens; HR, hazard ratio; MI, myocardial infarction; MPA, medroxyprogesterone acetate; NA, not applicable because women have had hysterectomy; PCI, percutaneous coronary intervention; PY, person-years. a The percentages are annualized. b Difference in estimated absolute excess risks (CEE plus MPA or CEE alone minus placebo). c For trend by age group. d Indicates CEE alone or CEE plus MPA. e Excludes non–melanoma skin cancer. Figure Legend:

6. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040 Health Outcomes in the Women’s Health Initiative Hormone Therapy Trials for the Overall Combined Phases (Cumulative Follow- up) According to 10-Year Age Groups at RandomizationCABG indicates coronary artery bypass graft; CEE, conjugated equine estrogens; HR, hazard ratio; MI, myocardial infarction; MPA, medroxyprogesterone acetate; NA, not applicable because women have had hysterectomy; PCI, percutaneous coronary intervention; PY, person-years. a The percentages are annualized. b Difference in estimated absolute excess risks (CEE plus MPA or CEE alone minus placebo). c For trend by age group. d Indicates CEE alone or CEE plus MPA. e Excludes non–melanoma skin cancer. Figure Legend: